Thyas Signs an Exclusive License Agreement with iPS Academia Japan (iPS-AJ) to Develop Autologous Immunotherapies

 Thyas Signs an Exclusive License Agreement with iPS Academia Japan (iPS-AJ) to Develop Autologous Immunotherapies

Thyas Signs an Exclusive License Agreement with iPS Academia Japan (iPS-AJ) to Develop Autologous Immunotherapies

Shots:

  • iPS Academia Japan to receive payments from Thyas. Thyas to get exclusive patent rights for production and usage of iPS cell-derived T cells, with non-exclusive rights for its development and commercialization
  • The focus of the agreement is to develop tumor-specific or virus-specific T cells using iPS’ technology, with proliferative capacity and potent killing capability for cancer and infectious diseases
  • Induced Pluripotent Stem (iPS) cells have purity, functionality and are KIR (Killer-immunoglobulin receptors) negative used for killing or targeting cancer or tumor cells

Click here to read full press release/ article | Ref: GlobeNewsWire | Image: Pitch

 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post